Concepts (248)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hippocampus | 36 | 2018 | 216 | 5.900 |
Why?
|
| Neurons | 35 | 2018 | 486 | 4.500 |
Why?
|
| Memory | 19 | 2017 | 202 | 3.400 |
Why?
|
| Action Potentials | 28 | 2017 | 212 | 2.910 |
Why?
|
| Models, Neurological | 25 | 2018 | 139 | 2.760 |
Why?
|
| Psychomotor Performance | 12 | 2018 | 108 | 2.660 |
Why?
|
| Nerve Net | 13 | 2016 | 137 | 2.450 |
Why?
|
| Prefrontal Cortex | 8 | 2014 | 85 | 2.330 |
Why?
|
| Macaca mulatta | 19 | 2019 | 340 | 2.050 |
Why?
|
| Memory, Short-Term | 8 | 2018 | 61 | 1.790 |
Why?
|
| Animals | 61 | 2019 | 8199 | 1.490 |
Why?
|
| CA1 Region, Hippocampal | 14 | 2017 | 39 | 1.330 |
Why?
|
| Electrodes, Implanted | 12 | 2018 | 54 | 1.320 |
Why?
|
| CA3 Region, Hippocampal | 12 | 2017 | 28 | 1.230 |
Why?
|
| Prostheses and Implants | 4 | 2016 | 48 | 1.220 |
Why?
|
| Cannabinoids | 7 | 2017 | 56 | 1.120 |
Why?
|
| Endocannabinoids | 4 | 2011 | 44 | 1.120 |
Why?
|
| Nonlinear Dynamics | 22 | 2018 | 77 | 1.090 |
Why?
|
| Rats | 30 | 2017 | 1895 | 1.080 |
Why?
|
| Brain | 10 | 2018 | 965 | 1.050 |
Why?
|
| Receptor, Cannabinoid, CB1 | 5 | 2011 | 68 | 0.990 |
Why?
|
| Microelectrodes | 4 | 2016 | 20 | 0.960 |
Why?
|
| Cognition Disorders | 6 | 2015 | 349 | 0.940 |
Why?
|
| Cognition | 8 | 2016 | 547 | 0.910 |
Why?
|
| Behavior, Animal | 12 | 2017 | 299 | 0.880 |
Why?
|
| Rats, Long-Evans | 17 | 2017 | 92 | 0.840 |
Why?
|
| Reward | 3 | 2010 | 64 | 0.810 |
Why?
|
| Executive Function | 2 | 2013 | 52 | 0.750 |
Why?
|
| Memory Disorders | 3 | 2016 | 49 | 0.640 |
Why?
|
| Electric Stimulation Therapy | 2 | 2018 | 19 | 0.620 |
Why?
|
| Synaptic Transmission | 5 | 2016 | 124 | 0.580 |
Why?
|
| Mental Recall | 1 | 2018 | 47 | 0.540 |
Why?
|
| Cocaine | 5 | 2012 | 354 | 0.530 |
Why?
|
| Neural Pathways | 7 | 2014 | 112 | 0.530 |
Why?
|
| Cerebral Cortex | 4 | 2011 | 143 | 0.510 |
Why?
|
| Sleep Deprivation | 2 | 2007 | 12 | 0.500 |
Why?
|
| Electrophysiology | 3 | 2012 | 76 | 0.500 |
Why?
|
| Prosthesis Design | 5 | 2016 | 107 | 0.490 |
Why?
|
| Male | 30 | 2019 | 19441 | 0.490 |
Why?
|
| Glutamic Acid | 2 | 2014 | 50 | 0.470 |
Why?
|
| Substance-Related Disorders | 2 | 2010 | 140 | 0.470 |
Why?
|
| Neuronal Plasticity | 3 | 2017 | 84 | 0.450 |
Why?
|
| Radiation Injuries | 2 | 2017 | 85 | 0.440 |
Why?
|
| Electric Stimulation | 6 | 2013 | 135 | 0.430 |
Why?
|
| Neuroprotective Agents | 2 | 2005 | 32 | 0.410 |
Why?
|
| Task Performance and Analysis | 4 | 2017 | 50 | 0.410 |
Why?
|
| Pyrazoles | 6 | 2011 | 77 | 0.400 |
Why?
|
| Computer Simulation | 11 | 2018 | 251 | 0.400 |
Why?
|
| Baclofen | 2 | 2013 | 26 | 0.390 |
Why?
|
| Benzoxazines | 6 | 2011 | 28 | 0.390 |
Why?
|
| Ceramics | 1 | 2013 | 7 | 0.390 |
Why?
|
| Morpholines | 6 | 2011 | 47 | 0.390 |
Why?
|
| Naphthalenes | 6 | 2011 | 53 | 0.380 |
Why?
|
| Piperidines | 6 | 2011 | 137 | 0.380 |
Why?
|
| Biofeedback, Psychology | 1 | 2012 | 12 | 0.360 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 2 | 2017 | 35 | 0.360 |
Why?
|
| Information Storage and Retrieval | 1 | 2012 | 26 | 0.360 |
Why?
|
| Perception | 1 | 2013 | 99 | 0.360 |
Why?
|
| User-Computer Interface | 2 | 2011 | 54 | 0.350 |
Why?
|
| Reaction Time | 4 | 2006 | 123 | 0.330 |
Why?
|
| Gene Expression Regulation | 2 | 2003 | 478 | 0.330 |
Why?
|
| Deep Brain Stimulation | 4 | 2015 | 52 | 0.320 |
Why?
|
| Frontal Lobe | 1 | 2010 | 35 | 0.320 |
Why?
|
| Signal Processing, Computer-Assisted | 5 | 2014 | 47 | 0.310 |
Why?
|
| Learning | 4 | 2013 | 84 | 0.310 |
Why?
|
| Neurophysiology | 1 | 2009 | 11 | 0.300 |
Why?
|
| Disease Models, Animal | 2 | 2011 | 1083 | 0.300 |
Why?
|
| Electrophysiological Phenomena | 4 | 2013 | 29 | 0.290 |
Why?
|
| Receptors, Drug | 3 | 2003 | 19 | 0.290 |
Why?
|
| Calcium | 3 | 2013 | 339 | 0.290 |
Why?
|
| Photic Stimulation | 3 | 2014 | 167 | 0.290 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2014 | 717 | 0.280 |
Why?
|
| Radiation Injuries, Experimental | 2 | 2019 | 37 | 0.280 |
Why?
|
| Neural Inhibition | 3 | 2017 | 33 | 0.280 |
Why?
|
| Behavior | 1 | 2008 | 29 | 0.280 |
Why?
|
| Serial Learning | 1 | 2008 | 2 | 0.270 |
Why?
|
| Sympathomimetics | 1 | 2007 | 5 | 0.270 |
Why?
|
| Neuropeptides | 1 | 2007 | 23 | 0.270 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2007 | 81 | 0.260 |
Why?
|
| Brain Injuries | 2 | 2018 | 75 | 0.250 |
Why?
|
| Analysis of Variance | 4 | 2014 | 471 | 0.250 |
Why?
|
| Brain Mapping | 4 | 2010 | 190 | 0.250 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2012 | 52 | 0.240 |
Why?
|
| Drug Tolerance | 2 | 2003 | 40 | 0.240 |
Why?
|
| Humans | 23 | 2018 | 32282 | 0.230 |
Why?
|
| Receptors, AMPA | 1 | 2005 | 16 | 0.230 |
Why?
|
| Nootropic Agents | 1 | 2005 | 13 | 0.230 |
Why?
|
| Wakefulness | 1 | 2005 | 25 | 0.230 |
Why?
|
| Ryanodine | 1 | 2005 | 4 | 0.230 |
Why?
|
| Epilepsy | 2 | 2017 | 79 | 0.220 |
Why?
|
| Positron-Emission Tomography | 3 | 2012 | 171 | 0.220 |
Why?
|
| Nerve Tissue Proteins | 2 | 2017 | 124 | 0.220 |
Why?
|
| Rats, Sprague-Dawley | 5 | 2014 | 897 | 0.220 |
Why?
|
| Algorithms | 9 | 2018 | 536 | 0.220 |
Why?
|
| Pattern Recognition, Visual | 1 | 2004 | 12 | 0.210 |
Why?
|
| Pyramidal Cells | 2 | 2006 | 18 | 0.210 |
Why?
|
| Genes, Immediate-Early | 1 | 2003 | 3 | 0.200 |
Why?
|
| Cytoskeletal Proteins | 1 | 2003 | 16 | 0.200 |
Why?
|
| Receptors, Cannabinoid | 4 | 2004 | 33 | 0.190 |
Why?
|
| Lidocaine | 1 | 2003 | 19 | 0.190 |
Why?
|
| Receptors, GABA-A | 1 | 2003 | 32 | 0.190 |
Why?
|
| Marijuana Abuse | 1 | 2003 | 18 | 0.190 |
Why?
|
| Nucleus Accumbens | 1 | 2004 | 121 | 0.190 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2003 | 82 | 0.190 |
Why?
|
| Random Allocation | 2 | 2013 | 247 | 0.190 |
Why?
|
| Data Interpretation, Statistical | 2 | 2012 | 116 | 0.180 |
Why?
|
| Carbamates | 2 | 2011 | 16 | 0.170 |
Why?
|
| Motor Activity | 4 | 2014 | 332 | 0.170 |
Why?
|
| Radiopharmaceuticals | 2 | 2012 | 95 | 0.170 |
Why?
|
| Benzamides | 2 | 2011 | 60 | 0.170 |
Why?
|
| Time Factors | 6 | 2019 | 2205 | 0.160 |
Why?
|
| Injections, Intravenous | 2 | 2012 | 99 | 0.160 |
Why?
|
| Dopamine | 2 | 2012 | 262 | 0.140 |
Why?
|
| Fibronectins | 1 | 2018 | 39 | 0.140 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2018 | 55 | 0.140 |
Why?
|
| Cerebrovascular Circulation | 1 | 2018 | 93 | 0.130 |
Why?
|
| Seizures | 1 | 2018 | 65 | 0.130 |
Why?
|
| Endothelium, Vascular | 1 | 2018 | 155 | 0.130 |
Why?
|
| Synapses | 1 | 2017 | 87 | 0.130 |
Why?
|
| Cerebrovascular Disorders | 1 | 2017 | 51 | 0.120 |
Why?
|
| Cranial Irradiation | 1 | 2017 | 94 | 0.120 |
Why?
|
| Extracellular Matrix | 1 | 2018 | 256 | 0.120 |
Why?
|
| Biological Clocks | 1 | 2015 | 6 | 0.120 |
Why?
|
| Equipment Design | 4 | 2009 | 178 | 0.110 |
Why?
|
| Likelihood Functions | 2 | 2013 | 50 | 0.110 |
Why?
|
| Pattern Recognition, Physiological | 1 | 2014 | 4 | 0.110 |
Why?
|
| Electrodes | 2 | 2013 | 20 | 0.110 |
Why?
|
| Probability Theory | 1 | 2014 | 2 | 0.110 |
Why?
|
| Glycine | 2 | 2013 | 26 | 0.110 |
Why?
|
| Psychotropic Drugs | 1 | 2014 | 12 | 0.110 |
Why?
|
| Oxazoles | 2 | 2005 | 7 | 0.110 |
Why?
|
| Monte Carlo Method | 3 | 2014 | 24 | 0.100 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2013 | 4 | 0.100 |
Why?
|
| Concept Formation | 1 | 2013 | 4 | 0.100 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2013 | 8 | 0.100 |
Why?
|
| Corpus Striatum | 1 | 2013 | 69 | 0.090 |
Why?
|
| ROC Curve | 4 | 2014 | 169 | 0.090 |
Why?
|
| Information Theory | 1 | 2011 | 4 | 0.090 |
Why?
|
| Pattern Recognition, Automated | 1 | 2012 | 36 | 0.090 |
Why?
|
| Cell Communication | 1 | 2011 | 37 | 0.090 |
Why?
|
| Biphenyl Compounds | 1 | 2011 | 21 | 0.090 |
Why?
|
| Computer Systems | 1 | 2011 | 15 | 0.090 |
Why?
|
| Dizocilpine Maleate | 1 | 2011 | 10 | 0.090 |
Why?
|
| Online Systems | 1 | 2011 | 11 | 0.090 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2011 | 28 | 0.090 |
Why?
|
| Injections | 1 | 2011 | 72 | 0.090 |
Why?
|
| 6-Cyano-7-nitroquinoxaline-2,3-dione | 1 | 2011 | 2 | 0.080 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2012 | 147 | 0.080 |
Why?
|
| Second Messenger Systems | 1 | 2011 | 8 | 0.080 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 1 | 2011 | 21 | 0.080 |
Why?
|
| Arachidonic Acids | 1 | 2011 | 29 | 0.080 |
Why?
|
| Macaca | 1 | 2010 | 30 | 0.080 |
Why?
|
| Radiation Dosage | 1 | 2011 | 91 | 0.080 |
Why?
|
| Phosphorylation | 1 | 2011 | 250 | 0.080 |
Why?
|
| Telemetry | 1 | 2009 | 24 | 0.070 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 637 | 0.070 |
Why?
|
| Exploratory Behavior | 1 | 2009 | 33 | 0.070 |
Why?
|
| Pilot Projects | 1 | 2011 | 553 | 0.070 |
Why?
|
| Video Recording | 1 | 2009 | 61 | 0.070 |
Why?
|
| Cocaine-Related Disorders | 1 | 2010 | 125 | 0.070 |
Why?
|
| Decision Making | 1 | 2010 | 189 | 0.070 |
Why?
|
| Administration, Intranasal | 1 | 2007 | 35 | 0.070 |
Why?
|
| Discriminant Analysis | 1 | 2007 | 20 | 0.070 |
Why?
|
| Glucose | 1 | 2007 | 160 | 0.060 |
Why?
|
| Electroencephalography | 2 | 2018 | 75 | 0.060 |
Why?
|
| Aging | 1 | 2013 | 942 | 0.060 |
Why?
|
| Orientation | 1 | 2006 | 29 | 0.060 |
Why?
|
| Multivariate Analysis | 1 | 2007 | 651 | 0.060 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2005 | 5 | 0.060 |
Why?
|
| Biomimetics | 1 | 2005 | 7 | 0.060 |
Why?
|
| Macrocyclic Compounds | 1 | 2005 | 2 | 0.060 |
Why?
|
| Dantrolene | 1 | 2005 | 3 | 0.060 |
Why?
|
| Estrenes | 1 | 2005 | 3 | 0.060 |
Why?
|
| Thionucleotides | 1 | 2005 | 5 | 0.060 |
Why?
|
| Okadaic Acid | 1 | 2005 | 6 | 0.060 |
Why?
|
| Pyrrolidinones | 1 | 2005 | 6 | 0.060 |
Why?
|
| N-Methylaspartate | 1 | 2005 | 13 | 0.060 |
Why?
|
| Rats, Inbred Strains | 1 | 2005 | 76 | 0.060 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2005 | 20 | 0.060 |
Why?
|
| Cyclohexanols | 1 | 2005 | 22 | 0.060 |
Why?
|
| Drug Interactions | 1 | 2005 | 86 | 0.060 |
Why?
|
| Cell Death | 1 | 2005 | 79 | 0.060 |
Why?
|
| Cyclic AMP | 1 | 2005 | 55 | 0.060 |
Why?
|
| Fetus | 1 | 2005 | 76 | 0.050 |
Why?
|
| Cell Culture Techniques | 1 | 2005 | 170 | 0.050 |
Why?
|
| Reproducibility of Results | 3 | 2014 | 757 | 0.050 |
Why?
|
| Hand | 1 | 2004 | 79 | 0.050 |
Why?
|
| Autoradiography | 1 | 2003 | 51 | 0.050 |
Why?
|
| Marine Toxins | 1 | 2003 | 4 | 0.050 |
Why?
|
| omega-Conotoxin GVIA | 1 | 2003 | 7 | 0.050 |
Why?
|
| Sodium Channel Blockers | 1 | 2003 | 7 | 0.050 |
Why?
|
| Enzyme Activators | 1 | 2003 | 8 | 0.050 |
Why?
|
| Interneurons | 1 | 2003 | 24 | 0.050 |
Why?
|
| Anesthetics, Local | 1 | 2004 | 85 | 0.050 |
Why?
|
| DNA, Complementary | 1 | 2002 | 31 | 0.050 |
Why?
|
| GABA Antagonists | 1 | 2003 | 14 | 0.050 |
Why?
|
| Patch-Clamp Techniques | 1 | 2003 | 76 | 0.050 |
Why?
|
| GABA Agonists | 1 | 2003 | 11 | 0.050 |
Why?
|
| Calcium Channel Blockers | 1 | 2003 | 53 | 0.050 |
Why?
|
| Receptors, GABA-B | 1 | 2003 | 19 | 0.050 |
Why?
|
| Models, Theoretical | 3 | 2012 | 139 | 0.050 |
Why?
|
| GTP-Binding Proteins | 1 | 2002 | 40 | 0.050 |
Why?
|
| Adaptation, Physiological | 1 | 2003 | 53 | 0.050 |
Why?
|
| Conditioning, Operant | 1 | 2003 | 122 | 0.050 |
Why?
|
| Signal Transduction | 2 | 2004 | 727 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2002 | 160 | 0.050 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2003 | 76 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2003 | 174 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2003 | 276 | 0.050 |
Why?
|
| Space Perception | 1 | 2002 | 30 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2014 | 128 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2002 | 183 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2003 | 499 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2002 | 315 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 556 | 0.040 |
Why?
|
| Linear Models | 2 | 2013 | 425 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2019 | 83 | 0.040 |
Why?
|
| Receptors, GABA | 1 | 2017 | 7 | 0.030 |
Why?
|
| Normal Distribution | 2 | 2009 | 14 | 0.030 |
Why?
|
| Vision, Ocular | 1 | 2017 | 33 | 0.030 |
Why?
|
| Temporal Lobe | 1 | 2017 | 34 | 0.030 |
Why?
|
| Gene Expression | 1 | 2018 | 346 | 0.030 |
Why?
|
| Computational Biology | 1 | 2017 | 99 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2017 | 107 | 0.030 |
Why?
|
| Feedback, Physiological | 1 | 2015 | 11 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2014 | 32 | 0.030 |
Why?
|
| Models, Statistical | 2 | 2006 | 187 | 0.030 |
Why?
|
| Whole-Body Irradiation | 1 | 2015 | 58 | 0.030 |
Why?
|
| Radiography | 1 | 2015 | 363 | 0.030 |
Why?
|
| Oxotremorine | 1 | 2013 | 3 | 0.020 |
Why?
|
| Resorcinols | 1 | 2013 | 7 | 0.020 |
Why?
|
| Spatial Behavior | 1 | 2013 | 11 | 0.020 |
Why?
|
| Muscarinic Agonists | 1 | 2013 | 8 | 0.020 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2013 | 17 | 0.020 |
Why?
|
| Analog-Digital Conversion | 1 | 2012 | 2 | 0.020 |
Why?
|
| Amplifiers, Electronic | 1 | 2012 | 3 | 0.020 |
Why?
|
| Electronics | 1 | 2012 | 15 | 0.020 |
Why?
|
| Primates | 1 | 2012 | 128 | 0.020 |
Why?
|
| Evoked Potentials | 1 | 2009 | 17 | 0.020 |
Why?
|
| Uncertainty | 1 | 2009 | 11 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2009 | 327 | 0.020 |
Why?
|
| Stochastic Processes | 1 | 2006 | 5 | 0.010 |
Why?
|
| Dendrites | 1 | 2006 | 17 | 0.010 |
Why?
|
| Equipment Failure Analysis | 1 | 2005 | 44 | 0.010 |
Why?
|
| Artificial Intelligence | 1 | 2005 | 63 | 0.010 |
Why?
|
| Adult | 1 | 2016 | 9259 | 0.010 |
Why?
|
| Cannabis | 1 | 2004 | 30 | 0.010 |
Why?
|
| Research | 1 | 2004 | 81 | 0.010 |
Why?
|